BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24295734)

  • 1. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
    Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
    Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
    Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
    Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
    Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
    Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
    Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
    Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.
    Gaudineau B; Fougère M; Guaddachi F; Lemoine F; de la Grange P; Jauliac S
    J Cell Sci; 2012 Oct; 125(Pt 19):4475-86. PubMed ID: 22767506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.
    Chung IH; Chen CY; Lin YH; Chi HC; Huang YH; Tai PJ; Liao CJ; Tsai CY; Lin SL; Wu MH; Chen CY; Lin KH
    Oncotarget; 2015 Jun; 6(17):15050-64. PubMed ID: 25940797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.
    Fougère M; Gaudineau B; Barbier J; Guaddachi F; Feugeas JP; Auboeuf D; Jauliac S
    Oncogene; 2010 Apr; 29(15):2292-301. PubMed ID: 20101218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipocalin 2 promotes breast cancer progression.
    Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer.
    Hu B; Zhang K; Li S; Li H; Yan Z; Huang L; Wu J; Han X; Jiang W; Mulatibieke T; Zheng L; Wan R; Wang X; Hu G
    Cancer Lett; 2016 Jul; 376(2):387-98. PubMed ID: 27085461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells.
    Tung MC; Hsieh SC; Yang SF; Cheng CW; Tsai RT; Wang SC; Huang MH; Hsieh YH
    Prostate; 2013 Sep; 73(12):1281-90. PubMed ID: 23775308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C/EBP ζ targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells.
    Wang L; Li H; Wang J; Gao W; Lin Y; Jin W; Chang G; Wang R; Li Q; Ma L; Pang T
    Biochim Biophys Acta; 2011 Oct; 1813(10):1803-13. PubMed ID: 21741997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia.
    Kobara H; Miyamoto T; Suzuki A; Asaka R; Yamada Y; Ishikawa K; Kikuchi N; Ohira S; Shiozawa T
    Placenta; 2013 Nov; 34(11):1036-43. PubMed ID: 23972287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.
    Wang X; Wang Y; Xiao G; Wang J; Zu L; Hao M; Sun X; Fu Y; Hu G; Wang J
    Oncotarget; 2016 May; 7(21):30350-64. PubMed ID: 27107418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
    Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
    Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.
    Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M
    BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.
    Guo P; Yang J; Jia D; Moses MA; Auguste DT
    Theranostics; 2016; 6(1):1-13. PubMed ID: 26722369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HGF mediated upregulation of lipocalin 2 regulates MMP9 through nuclear factor-κB activation.
    Koh SA; Lee KH
    Oncol Rep; 2015 Oct; 34(4):2179-87. PubMed ID: 26259977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.